Evidence map›Paper›PMID 24986919›Full record

ArticleHuman molecular genetics2014

CGG repeats in RNA modulate expression of TDP-43 in mouse and fly models of fragile X tremor ataxia syndrome.

Jocelyn N Galloway, Chad Shaw, Peng Yu, Deena Parghi, Mickael Poidevin, Peng Jin, David L Nelson

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. The Expanding Toolkit of Translating Ribosome Affinity Purification.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017
    Article
  7. Review
  8. Review
  9. Frontiers in cellular neuroscience · 2017
    Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jocelyn N GallowayInterdepartmental Program in Cell and Molecular Biology.
Chad ShawDepartment of Human and Molecular Genetics and.
Peng YuDepartment of Human and Molecular Genetics and.
Deena ParghiDepartment of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA and.
Mickael PoidevinDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Peng JinDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA.
David L NelsonInterdepartmental Program in Cell and Molecular Biology, Department of Human and Molecular Genetics and nelson@bcm.edu.
Emory University · USInstitute of Molecular and Cell Biology · RUBaylor College of Medicine · US

Funding

UNDERSTANDING FXTAS AMONG MALES WITH THE FMR1 PREMUTATIONP30HD024064 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI ROSENMUND, CHRISTIAN · 1988 to 2013
$29.4M
Molecular Basis of rCGG-Mediated NeurodegenerationR01NS051630 · NINDS · EMORY UNIVERSITY · PI NELSON, DAVID LOREN · 2006 to 2023
$9.8M
Steps towards a paternal gene activation therapy for Angelman syndromeU54HD083092 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI NELSON, DAVID LOREN, NEUL, JEFFREY L · 2014 to 2019
$7.8M
Developing therapeutic intervention for FXTASR21NS067461 · NINDS · EMORY UNIVERSITY · PI JIN, PENG · 2010 to 2011
$438k
NICHD NIH HHS HD24064NICHD NIH HHS P30 HD024064NICHD NIH HHS U54 HD083092NINDS NIH HHS NS051630NINDS NIH HHS NS67461NINDS NIH HHS R01 NS051630
6 · The paper itself

Abstract

Determining the molecular mechanism(s) leading to Purkinje neuron loss in the neurodegenerative disorder fragile X-associated tremor/ataxia syndrome (FXTAS) is limited by the complex morphology of this cell type. Purkinje neurons are notoriously difficult to isolate and maintain in culture presenting considerable difficultly to identify molecular changes in response to expanded CGG repeat (rCGG)-containing mRNA that induces neurotoxicity in FXTAS. Several studies have uncovered a number of RNA-binding proteins involved in translation that aberrantly interact with the CGG-containing RNA; however, whether these interactions alter the translational profile of cells has not been investigated. Here we employ bacTRAP translational profiling to demonstrate that Purkinje neurons ectopically expressing 90 CGG repeats exhibit a dramatic change in their translational profile even prior to the onset of rCGG-induced phenotypes. This approach identified ∼500 transcripts that are differentially associated with ribosomes in r(CGG)₉₀-expressing mice. Functional annotation cluster analysis revealed broad ontologies enriched in the r(CGG)₉₀ list, including RNA binding and response to stress. Intriguingly, a transcript for the Tardbp gene, implicated in a number of other neurodegenerative disorders, exhibits altered association with ribosomes in the presence of r(CGG)₉₀ repeats. We therefore tested and showed that reduced association of Tardbp mRNA with the ribosomes results in a loss of TDP-43 protein expression in r(CGG)₉₀-expressing Purkinje neurons. Furthermore, we showed that TDP-43 could modulate the rCGG repeat-mediated toxicity in a Drosophila model that we developed previously. These findings together suggest that translational dysregulation may be an underlying mechanism of rCGG-induced neurotoxicity in FXTAS.

Indexed as

Trinucleotide Repeat ExpansionAnimalsAnimals, Genetically ModifiedAtaxiaDisease Models, AnimalDNA-Binding ProteinsDrosophilaDrosophila ProteinsFragile X SyndromeHumansMiceMice, Inbred C57BLMolecular Sequence DataProtein BiosynthesisPurkinje CellsRibosomesDNA-Binding ProteinsDrosophila ProteinsRNA, MessengerTardbp protein, mouseTBPH protein, Drosophila

Identifiers

PMID24986919
PMCPMC4204772
OpenAlexW2062727849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.